Canine Immune Mediated Hemolytic Anemia
By DVM Rounds·April 1, 2026·1 question
🩺Internal Medicine🚨Emergency💊Pharmacology
🧭 Routing
This is a critical case of confirmed IMHA with severe anemia (PCV 14%) requiring immediate stabilization, transfusion management, and a comprehensive immunosuppressive and anticoagulation protocol. Internal Medicine will lead on the overall IMHA management and long-term immunosuppression. Emergency is crucial for acute stabilization, transfusion thresholds, and critical care. Pharmacology will provide expertise on optimizing drug protocols, potential interactions, and dose adjustments for the immunosuppressants and anticoagulants.
🩺Elena VasquezInternal Medicine Specialist
Colleague, this is a classic and severe presentation of IMHA. Good job confirming it with saline agglutination. Here is the multi-faceted protocol I would initiate immediately.
1. Immunosuppression:
* Prednisone: Start at a true immunosuppressive dose of 2 mg/kg/day. I typically divide this BID for the first few days to maintain steady levels.
* Second Agent: My preference is Mycophenolate Mofetil at 8-12 mg/kg PO BID. It has a faster onset of action (3-5 days) compared to azathioprine. The main side effect to watch for is dose-dependent diarrhea. If cost or availability is an issue, Azathioprine at 2 mg/kg PO q24h for 1-2 weeks, then tapered to q48h, is a reasonable alternative. Remember, azathioprine can take 1-2 weeks to become effective.
2. Thromboprophylaxis (Non-negotiable):
Pulmonary thromboembolism is the leading cause of death in these cases.
* Clopidogrel: Start at 2 mg/kg PO q24h. Continue for the duration of the immunosuppressive therapy, as the risk persists as long as the disease is active.
3. Transfusion Guidelines:
There is no "magic number" for a transfusion threshold; it's about the patient's clinical status.
* Decision Points: Transfuse based on clinical signs of anemia: tachycardia (>160 bpm), tachypnea/dyspnea, profound weakness, or collapse.
* With a PCV of 14%, this patient is on the edge. If she is tachycardic, tachypneic at rest, or overtly weak, I would transfuse one unit of pRBCs now. If she is surprisingly stable, you could hold off, but be prepared to transfuse at a moment's notice. The goal of transfusion is to buy time for the immunosuppressive drugs to work.
4. Monitoring & Supportive Care:
* Monitoring: Check PCV/TS q12h for the first 48-72 hours to assess for a continued drop, stabilization, or rise. Monitor reticulocyte count and bilirubin daily to trend hemolysis and regeneration.
* GI Protection: High-dose steroids will cause significant GI upset. Start omeprazole at 1 mg/kg PO BID.
* Underlying Triggers: If you haven't already, run a tick-borne disease panel and perform a thorough neoplasia screen (thoracic radiographs, abdominal ultrasound). While most IMHA is primary, we must rule out secondary causes.
This is a critical period. Aggressive, multi-modal therapy upfront gives these patients the best chance.
Confidence Level: High confidence. This is the standard of care.
1. Immunosuppression:
* Prednisone: Start at a true immunosuppressive dose of 2 mg/kg/day. I typically divide this BID for the first few days to maintain steady levels.
* Second Agent: My preference is Mycophenolate Mofetil at 8-12 mg/kg PO BID. It has a faster onset of action (3-5 days) compared to azathioprine. The main side effect to watch for is dose-dependent diarrhea. If cost or availability is an issue, Azathioprine at 2 mg/kg PO q24h for 1-2 weeks, then tapered to q48h, is a reasonable alternative. Remember, azathioprine can take 1-2 weeks to become effective.
2. Thromboprophylaxis (Non-negotiable):
Pulmonary thromboembolism is the leading cause of death in these cases.
* Clopidogrel: Start at 2 mg/kg PO q24h. Continue for the duration of the immunosuppressive therapy, as the risk persists as long as the disease is active.
3. Transfusion Guidelines:
There is no "magic number" for a transfusion threshold; it's about the patient's clinical status.
* Decision Points: Transfuse based on clinical signs of anemia: tachycardia (>160 bpm), tachypnea/dyspnea, profound weakness, or collapse.
* With a PCV of 14%, this patient is on the edge. If she is tachycardic, tachypneic at rest, or overtly weak, I would transfuse one unit of pRBCs now. If she is surprisingly stable, you could hold off, but be prepared to transfuse at a moment's notice. The goal of transfusion is to buy time for the immunosuppressive drugs to work.
4. Monitoring & Supportive Care:
* Monitoring: Check PCV/TS q12h for the first 48-72 hours to assess for a continued drop, stabilization, or rise. Monitor reticulocyte count and bilirubin daily to trend hemolysis and regeneration.
* GI Protection: High-dose steroids will cause significant GI upset. Start omeprazole at 1 mg/kg PO BID.
* Underlying Triggers: If you haven't already, run a tick-borne disease panel and perform a thorough neoplasia screen (thoracic radiographs, abdominal ultrasound). While most IMHA is primary, we must rule out secondary causes.
This is a critical period. Aggressive, multi-modal therapy upfront gives these patients the best chance.
Confidence Level: High confidence. This is the standard of care.
🚨Marcus ColeEmergency Specialist
Alright, we have a critical IMHA case. The PCV of 14% with evidence of active hemolysis puts this dog squarely in the life-threatening category. My priorities are immediate: improve oxygen-carrying capacity to prevent hypoxic organ injury and mitigate the massive risk of thromboembolism.
1. Transfusion:
The decision to transfuse is clinical, not just based on the number. However, a PCV this low, coupled with the acuity of the disease, almost always warrants it. We're not aiming for a normal PCV, just enough to get them out of the immediate danger zone and reduce the signs of decompensatory shock (tachycardia, tachypnea, weakness).
My Transfusion Specialist has provided an excellent protocol. Key takeaways:
* Product & Volume: We'll use crossmatched pRBCs. Based on their calculations, we'll need approximately 130-135 mL to reach a conservative target PCV of 22%.
* Administration: This is critical. We must start slow (0.25-1 mL/kg/hr for 15-30 min) while monitoring vitals every 5 minutes for a reaction. If stable, we can increase the rate to finish within 4 hours. A dedicated IV line with 0.9% NaCl only.
* Monitoring: Constant vigilance for signs of an immunologic reaction (fever, tachycardia, facial swelling) or volume overload is non-negotiable. We'll check a post-transfusion PCV 1-2 hours after completion.
2. Anticoagulation:
This is just as important as the transfusion. These patients are profoundly hypercoagulable. I would start anticoagulation immediately, not after the PCV improves. My typical protocol is dual therapy:
* Clopidogrel: 2-3 mg/kg PO loading dose, then 1-2 mg/kg PO SID.
* Rivaroxaban (1-2 mg/kg PO SID) OR Enoxaparin (0.8 mg/kg SQ q6h). The choice depends on clinician preference and owner ability to administer, but we need an anticoagulant on board now.
3. Immunosuppression:
This is the definitive treatment, and we need to get it started.
* Glucocorticoids: Prednisone at 2 mg/kg/day is the cornerstone.
* Second Agent: This is where I collaborate with Internal Medicine. Dr. Vasquez will manage the long-term plan, but for the acute phase, my preference is mycophenolate (10-15 mg/kg PO BID) due to its faster onset of action compared to azathioprine. We can start that now pending her input.
4. Monitoring Plan (ICU):
* Vitals: Continuous ECG, serial blood pressure, and respiratory rate/effort monitoring q1-2h. Any sudden spike in respiratory effort is a high-priority alarm for a pulmonary thromboembolism (PTE).
* Labs: PCV/TS q6-12h to assess response and ongoing hemolysis.
* Supportive Care: Strict cage rest, IV fluids to maintain hydration (be cautious of overload), and gastroprotectants (e.g., omeprazole) are standard.
In short: transfuse carefully, start aggressive anticoagulation and immunosuppression now, and monitor like a hawk for PTE. Once we're through the initial 24-48 hours, this becomes a case for Dr. Vasquez to fine-tune long-term.
1. Transfusion:
The decision to transfuse is clinical, not just based on the number. However, a PCV this low, coupled with the acuity of the disease, almost always warrants it. We're not aiming for a normal PCV, just enough to get them out of the immediate danger zone and reduce the signs of decompensatory shock (tachycardia, tachypnea, weakness).
My Transfusion Specialist has provided an excellent protocol. Key takeaways:
* Product & Volume: We'll use crossmatched pRBCs. Based on their calculations, we'll need approximately 130-135 mL to reach a conservative target PCV of 22%.
* Administration: This is critical. We must start slow (0.25-1 mL/kg/hr for 15-30 min) while monitoring vitals every 5 minutes for a reaction. If stable, we can increase the rate to finish within 4 hours. A dedicated IV line with 0.9% NaCl only.
* Monitoring: Constant vigilance for signs of an immunologic reaction (fever, tachycardia, facial swelling) or volume overload is non-negotiable. We'll check a post-transfusion PCV 1-2 hours after completion.
2. Anticoagulation:
This is just as important as the transfusion. These patients are profoundly hypercoagulable. I would start anticoagulation immediately, not after the PCV improves. My typical protocol is dual therapy:
* Clopidogrel: 2-3 mg/kg PO loading dose, then 1-2 mg/kg PO SID.
* Rivaroxaban (1-2 mg/kg PO SID) OR Enoxaparin (0.8 mg/kg SQ q6h). The choice depends on clinician preference and owner ability to administer, but we need an anticoagulant on board now.
3. Immunosuppression:
This is the definitive treatment, and we need to get it started.
* Glucocorticoids: Prednisone at 2 mg/kg/day is the cornerstone.
* Second Agent: This is where I collaborate with Internal Medicine. Dr. Vasquez will manage the long-term plan, but for the acute phase, my preference is mycophenolate (10-15 mg/kg PO BID) due to its faster onset of action compared to azathioprine. We can start that now pending her input.
4. Monitoring Plan (ICU):
* Vitals: Continuous ECG, serial blood pressure, and respiratory rate/effort monitoring q1-2h. Any sudden spike in respiratory effort is a high-priority alarm for a pulmonary thromboembolism (PTE).
* Labs: PCV/TS q6-12h to assess response and ongoing hemolysis.
* Supportive Care: Strict cage rest, IV fluids to maintain hydration (be cautious of overload), and gastroprotectants (e.g., omeprazole) are standard.
In short: transfuse carefully, start aggressive anticoagulation and immunosuppression now, and monitor like a hawk for PTE. Once we're through the initial 24-48 hours, this becomes a case for Dr. Vasquez to fine-tune long-term.
Transfusion Specialist
For a 12 kg Cocker Spaniel with a PCV of 14%, to raise the PCV to a target of 22% using packed red blood cells (pRBCs) with a PCV of 65%, the following volume is needed:
* Formula: Volume of RBCs needed (mL) = [Weight (kg) x Blood Volume (mL/kg) x (Target PCV - Current PCV)] / PCV of product
* Assumptions:
* Weight = 12 kg
* Current PCV = 14% (0.14)
* Target PCV = 22% (0.22)
* PCV of pRBC product = 65% (0.65)
* Estimated blood volume for a dog = 90 mL/kg (using the higher end for an anemic patient)
* Calculation:
1. Desired increase in PCV = 0.22 - 0.14 = 0.08
2. Total volume of pure RBCs needed = 12 kg 90 mL/kg 0.08 = 86.4 mL
3. Volume of pRBC product needed = 86.4 mL / 0.65 = 132.9 mL
Therefore, approximately 130-135 mL of pRBCs would be needed to reach the target PCV of 22%.
A. Pre-transfusion Preparation:
Blood Typing & Crossmatch:
* Essential: Perform a major and minor crossmatch. Given the IMHA, autoagglutination may complicate blood typing, but crossmatching is critical to minimize reaction risk.
* If possible, determine DEA 1.1 status of the recipient for future transfusions.
Product Preparation:
* Warm pRBCs to room temperature (not above 37°C) using a warm water bath or blood warmer. Do not microwave.
* Ensure product integrity (no clots, discoloration).
IV Access:
* Establish a dedicated intravenous catheter (preferably 18-20 gauge) for the transfusion.
* Use an in-line blood filter (170-260 micron) to remove microaggregates.
* Flush the line with 0.9% NaCl. Never administer with calcium-containing fluids (e.g., LRS) through the same line as it can chelate citrate and cause clots.
Baseline Assessment:
* Record baseline vital parameters: heart rate (HR), respiratory rate (RR), temperature (Temp), blood pressure (BP), mucous membrane color, capillary refill time (CRT), and mentation.
* Collect a pre-transfusion PCV/TS.
Premedication (Optional/Considered):
* Antihistamines (e.g., diphenhydramine) and/or corticosteroids (e.g., dexamethasone) may be considered for patients with a history of transfusion reactions or severe allergic tendencies. However, for a first transfusion, it's often avoided to allow for easier identification of a reaction. Given the IMHA, corticosteroids are already part of the treatment.
B. Transfusion Administration:
Slow Initial Rate:
* Begin the transfusion slowly for the first 15-30 minutes (e.g., 0.25-1 mL/kg/hr) to monitor for acute reactions.
Increase Rate:
* If no adverse reactions are observed, increase the rate to complete the transfusion within 4 hours (typically 5-10 mL/kg/hr). Prolonged administration increases the risk of bacterial growth and RBC degradation.
Fluid Compatibility:
* Only 0.9% NaCl should be administered concurrently through the same IV line.
C. Monitoring Protocol:
During Transfusion:
* First 15-30 minutes: Monitor HR, RR, Temp, and mucous membranes every 5 minutes.
* Thereafter: Monitor HR, RR, Temp, mucous membranes, CRT, and mentation every 15-30 minutes until completion.
* Watch for signs of acute transfusion reactions:
* Immunologic: Fever, tachycardia, tachypnea, vomiting, diarrhea, urticaria, facial swelling, pruritus, tremors, hypotension, collapse, hemoglobinuria (red urine).
* Non-immunologic: Circulatory overload (coughing, dyspnea, crackles, serous nasal discharge), hypothermia, citrate toxicity (muscle tremors, arrhythmias), bacterial contamination (fever, shock).
Post-transfusion:
* Immediate Post-transfusion: Repeat PCV/TS 1-2 hours after the transfusion is complete to assess efficacy and rule out immediate hemolysis.
* Ongoing Monitoring: Continue to monitor vital parameters for several hours.
* Delayed Reactions: Monitor for signs of delayed hemolytic transfusion reactions (PCV drop 2-21 days post-transfusion, icterus, hemoglobinuria) or other delayed non-hemolytic reactions (e.g., fever, lethargy) for several days.
D. Reassessment and Further Action:
* The target PCV of 22% is an initial stabilization goal. The patient's clinical signs (mentation, weakness, heart rate, respiratory effort) are paramount.
* Reassess PCV/TS and clinical status regularly. Further transfusions may be necessary depending on the ongoing rate of hemolysis and the bone marrow's response to treatment.
1. pRBC Volume Calculation
* Formula: Volume of RBCs needed (mL) = [Weight (kg) x Blood Volume (mL/kg) x (Target PCV - Current PCV)] / PCV of product
* Assumptions:
* Weight = 12 kg
* Current PCV = 14% (0.14)
* Target PCV = 22% (0.22)
* PCV of pRBC product = 65% (0.65)
* Estimated blood volume for a dog = 90 mL/kg (using the higher end for an anemic patient)
* Calculation:
1. Desired increase in PCV = 0.22 - 0.14 = 0.08
2. Total volume of pure RBCs needed = 12 kg 90 mL/kg 0.08 = 86.4 mL
3. Volume of pRBC product needed = 86.4 mL / 0.65 = 132.9 mL
Therefore, approximately 130-135 mL of pRBCs would be needed to reach the target PCV of 22%.
2. Standard Administration and Monitoring Protocol
A. Pre-transfusion Preparation:
* Essential: Perform a major and minor crossmatch. Given the IMHA, autoagglutination may complicate blood typing, but crossmatching is critical to minimize reaction risk.
* If possible, determine DEA 1.1 status of the recipient for future transfusions.
* Warm pRBCs to room temperature (not above 37°C) using a warm water bath or blood warmer. Do not microwave.
* Ensure product integrity (no clots, discoloration).
* Establish a dedicated intravenous catheter (preferably 18-20 gauge) for the transfusion.
* Use an in-line blood filter (170-260 micron) to remove microaggregates.
* Flush the line with 0.9% NaCl. Never administer with calcium-containing fluids (e.g., LRS) through the same line as it can chelate citrate and cause clots.
* Record baseline vital parameters: heart rate (HR), respiratory rate (RR), temperature (Temp), blood pressure (BP), mucous membrane color, capillary refill time (CRT), and mentation.
* Collect a pre-transfusion PCV/TS.
* Antihistamines (e.g., diphenhydramine) and/or corticosteroids (e.g., dexamethasone) may be considered for patients with a history of transfusion reactions or severe allergic tendencies. However, for a first transfusion, it's often avoided to allow for easier identification of a reaction. Given the IMHA, corticosteroids are already part of the treatment.
B. Transfusion Administration:
* Begin the transfusion slowly for the first 15-30 minutes (e.g., 0.25-1 mL/kg/hr) to monitor for acute reactions.
* If no adverse reactions are observed, increase the rate to complete the transfusion within 4 hours (typically 5-10 mL/kg/hr). Prolonged administration increases the risk of bacterial growth and RBC degradation.
* Only 0.9% NaCl should be administered concurrently through the same IV line.
C. Monitoring Protocol:
* First 15-30 minutes: Monitor HR, RR, Temp, and mucous membranes every 5 minutes.
* Thereafter: Monitor HR, RR, Temp, mucous membranes, CRT, and mentation every 15-30 minutes until completion.
* Watch for signs of acute transfusion reactions:
* Immunologic: Fever, tachycardia, tachypnea, vomiting, diarrhea, urticaria, facial swelling, pruritus, tremors, hypotension, collapse, hemoglobinuria (red urine).
* Non-immunologic: Circulatory overload (coughing, dyspnea, crackles, serous nasal discharge), hypothermia, citrate toxicity (muscle tremors, arrhythmias), bacterial contamination (fever, shock).
* Immediate Post-transfusion: Repeat PCV/TS 1-2 hours after the transfusion is complete to assess efficacy and rule out immediate hemolysis.
* Ongoing Monitoring: Continue to monitor vital parameters for several hours.
* Delayed Reactions: Monitor for signs of delayed hemolytic transfusion reactions (PCV drop 2-21 days post-transfusion, icterus, hemoglobinuria) or other delayed non-hemolytic reactions (e.g., fever, lethargy) for several days.
D. Reassessment and Further Action:
* The target PCV of 22% is an initial stabilization goal. The patient's clinical signs (mentation, weakness, heart rate, respiratory effort) are paramount.
* Reassess PCV/TS and clinical status regularly. Further transfusions may be necessary depending on the ongoing rate of hemolysis and the bone marrow's response to treatment.
💊Nadia VossPharmacology Specialist
This is a critical case requiring a multi-faceted approach. I'll focus on the pharmacology of your therapeutic options, while Dr. Vasquez can integrate this into the overall treatment strategy and Dr. Cole can address the immediate stabilization.
Immunosuppression: Mycophenolate vs. Azathioprine
This is the central pharmacological decision. Both are typically used in conjunction with immunosuppressive doses of prednisone (e.g., 2 mg/kg/day initially).
Mycophenolate Mofetil:
* Mechanism: Inhibits inosine monophosphate dehydrogenase, an enzyme crucial for de novo purine synthesis in lymphocytes. This makes it relatively specific for T and B cells.
* Onset: Rapid, typically within days. This is its primary advantage in an acute, severe IMHA case.
* Adverse Effects: Primarily dose-dependent gastrointestinal upset (diarrhea, vomiting). Starting at a lower dose and titrating up can mitigate this.
* Key Interaction: Absorption is pH-dependent. Concurrent administration of proton pump inhibitors (e.g., omeprazole) or antacids can decrease its bioavailability. If a gastroprotectant is used, an H2 blocker like famotidine may be a better choice, or separate administration by at least 2 hours.
Azathioprine:
* Mechanism: Purine analog that incorporates into DNA, disrupting cell proliferation, primarily targeting lymphocytes.
* Onset: Slow. It can take 2-4 weeks to reach full therapeutic effect, making it less ideal for the initial induction phase of a fulminant case.
* Adverse Effects: Potential for dose-dependent myelosuppression and hepatotoxicity. Requires regular monitoring of CBC and liver enzymes (e.g., q2 weeks initially). This monitoring burden is a significant consideration.
Pharmacologic Recommendation: For this acute, severe presentation (PCV 14%, high bilirubin), mycophenolate's rapid onset is a significant advantage. The main hurdle is managing potential GI side effects and the interaction with PPIs.
Anticoagulation
Thromboembolism is a leading cause of mortality in IMHA, so thromboprophylaxis is not optional.
* Clopidogrel: This is the current standard of care. It's an irreversible P2Y12 ADP receptor antagonist, preventing platelet aggregation. It has demonstrated superiority over low-dose aspirin for preventing thrombosis in high-risk dogs.
* Rivaroxaban/Apixaban: Oral Factor Xa inhibitors are also excellent options and may be used in combination with clopidogrel in very high-risk patients. Dr. Vasquez or Cole can speak to the evidence for dual therapy.
* Aspirin: Largely supplanted by clopidogrel due to weaker efficacy and a higher risk of GI ulceration, especially when combined with high-dose corticosteroids. I would not recommend it as a first-line agent here.
Supportive Pharmacology
* Gastroprotection: Due to the high-dose prednisone, a gastroprotectant is indicated. As noted above, if using mycophenolate, be mindful of the PPI interaction. Famotidine is a reasonable alternative, though less potent than omeprazole for preventing steroid-induced ulceration.
* Transfusion: Dr. Cole will manage this, but from a pharmacologic standpoint, ensure any premedications (e.g., diphenhydramine) do not have unforeseen interactions with the patient's current drug regimen.
In summary, my recommendation from a purely pharmacological perspective would be a protocol including prednisone, mycophenolate (for rapid onset), and clopidogrel, with careful consideration for the choice of gastroprotectant to ensure mycophenolate absorption is not compromised. Dr. Vasquez will determine the final protocol based on the complete clinical picture.
Immunosuppression: Mycophenolate vs. Azathioprine
This is the central pharmacological decision. Both are typically used in conjunction with immunosuppressive doses of prednisone (e.g., 2 mg/kg/day initially).
* Mechanism: Inhibits inosine monophosphate dehydrogenase, an enzyme crucial for de novo purine synthesis in lymphocytes. This makes it relatively specific for T and B cells.
* Onset: Rapid, typically within days. This is its primary advantage in an acute, severe IMHA case.
* Adverse Effects: Primarily dose-dependent gastrointestinal upset (diarrhea, vomiting). Starting at a lower dose and titrating up can mitigate this.
* Key Interaction: Absorption is pH-dependent. Concurrent administration of proton pump inhibitors (e.g., omeprazole) or antacids can decrease its bioavailability. If a gastroprotectant is used, an H2 blocker like famotidine may be a better choice, or separate administration by at least 2 hours.
* Mechanism: Purine analog that incorporates into DNA, disrupting cell proliferation, primarily targeting lymphocytes.
* Onset: Slow. It can take 2-4 weeks to reach full therapeutic effect, making it less ideal for the initial induction phase of a fulminant case.
* Adverse Effects: Potential for dose-dependent myelosuppression and hepatotoxicity. Requires regular monitoring of CBC and liver enzymes (e.g., q2 weeks initially). This monitoring burden is a significant consideration.
Pharmacologic Recommendation: For this acute, severe presentation (PCV 14%, high bilirubin), mycophenolate's rapid onset is a significant advantage. The main hurdle is managing potential GI side effects and the interaction with PPIs.
Anticoagulation
Thromboembolism is a leading cause of mortality in IMHA, so thromboprophylaxis is not optional.
* Clopidogrel: This is the current standard of care. It's an irreversible P2Y12 ADP receptor antagonist, preventing platelet aggregation. It has demonstrated superiority over low-dose aspirin for preventing thrombosis in high-risk dogs.
* Rivaroxaban/Apixaban: Oral Factor Xa inhibitors are also excellent options and may be used in combination with clopidogrel in very high-risk patients. Dr. Vasquez or Cole can speak to the evidence for dual therapy.
* Aspirin: Largely supplanted by clopidogrel due to weaker efficacy and a higher risk of GI ulceration, especially when combined with high-dose corticosteroids. I would not recommend it as a first-line agent here.
Supportive Pharmacology
* Gastroprotection: Due to the high-dose prednisone, a gastroprotectant is indicated. As noted above, if using mycophenolate, be mindful of the PPI interaction. Famotidine is a reasonable alternative, though less potent than omeprazole for preventing steroid-induced ulceration.
* Transfusion: Dr. Cole will manage this, but from a pharmacologic standpoint, ensure any premedications (e.g., diphenhydramine) do not have unforeseen interactions with the patient's current drug regimen.
In summary, my recommendation from a purely pharmacological perspective would be a protocol including prednisone, mycophenolate (for rapid onset), and clopidogrel, with careful consideration for the choice of gastroprotectant to ensure mycophenolate absorption is not compromised. Dr. Vasquez will determine the final protocol based on the complete clinical picture.
Related Cases
Egg Binding Bird Emergency Treatment
🦜 Avian🚨 Emergency💊 Pharmacology
1 question
Hepatic Lipidosis Cat Feeding Tube Nutrition
🥗 Nutrition🩺 Internal Medicine🚨 Emergency
1 question
Canine Glaucoma Emergency Treatment
👁️ Ophthalmology🚨 Emergency💊 Pharmacology
1 question
Canine Pancreatitis Treatment Protocol
🩺 Internal Medicine🚨 Emergency🥗 Nutrition
1 question
Canine Addison Disease Crisis Treatment
🚨 Emergency🩺 Internal Medicine
1 question
Canine Pyometra Surgery Emergency
🚨 Emergency🔪 Surgery🩺 Internal Medicine
1 question
Get Instant Specialist Consults
DVM Rounds connects you with 13 AI veterinary specialists and 45+ sub-agents. Ask any clinical question and get comprehensive, multi-specialist answers in seconds.
Start Free — No Credit Card